Multiple Myeloma: Current Advances and Future Directions

DOI IR IR (HANDLE) Web Site Web Site 24 References Open Access
  • Murakami Hirokazu
    Professor, Gunma University of Health and Welfare Professor Emeritus, Gunma University

Bibliographic Information

Other Title
  • 多発性骨髄腫診療の進歩と将来
  • タハツセイ コツズイシュ シンリョウ ノ シンポ ト ショウライ

Search this article

Description

<p>Twenty years ago, the prognosis of multiple myeloma has been extremely poor, and myeloma was known as incurable disease. However, the treatment performance of myeloma improved by the development of novel agents, including immunomodulatory drugs such as thalidomide, proteasome inhibitor such as bortezomib, and anti-myeloma monoclonal antibody such as daratumumab, and the plateau of survival curve was obtained now. In addition to the improvement of treatment, the new inspection methods of minimal residual disease were developed, and the accuracy of determination of treatment efficacy improved. According to these advances, we now came to be able to make precise therapeutic strategy. Hereafter, the strong immune-therapy including the CAR-T may be introduced in clinical practice, it’s no exaggeration to say that I can expect the cure of myeloma.</p>

Journal

References(24)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top